Sep, 2020

U.S.A.
News / Corporate
Astellas Establishes Global Patient Centricity Leadership Structure to Incorporate Patient Perspectives Across Research and Development Continuum
Astellas today announced the structure and operating model for its global Patient Centricity organization designed to support the development of innovative health solutions through a deep...
Read More

Jul, 2020

U.S.A.
News / Corporate
Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research
Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D., "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc., and LabCentral, a launchpad for early-stage...
Read More
U.S.A.
News / Corporate
Astellas is Awarded Grant from the U.S. National Institutes of Health (NIH) to Fund Early Clinical Studies of ASP8062 to Investigate Potential Novel Therapeutic Approach to Address the Opioid Crisis
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the...
Read More

May, 2020

U.S.A.
News / Corporate
FDA Approves VESIcare LS™ (solifenacin succinate) Oral Suspension for Pediatric Patients
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved VESIcare LS™ (solifenacin...
Read More
U.S.A.
News / Corporate
Astellas Pharma Support Solutions Help to Address Evolving Patient Needs During COVID-19
With more and more Americans facing economic hardships as a result of the COVID-19 pandemic, Astellas has implemented changes to its patient assistance programs as part of the company's ongoing...
Read More